I study microplastics and toxic chemicals. That's why my family doesn't wear shoes in the house.
Microplastics from car tires and garbage, as well as street runoff, can be tracked indoors on shoes.
The researcher thinks her kids' Japanese heritage helped them adopt the habit.
This as-told-to essay is based on a conversation with Tracey Woodruff, the director of the Program on Reproductive Health & the Environment at the University of California, San Francisco. She studies how microplastics and toxic chemicals impact fertility and child development. The below has been edited for length and clarity.
I did not grow up removing shoes when entering the house.
My husband and I started getting into the habit when we had kids, and I got more immersed in my research and how to lower exposures to toxic chemicals.
One of the things that can help reduce exposure to microplastics and other toxic chemicals is taking your shoes off before coming into the house to avoid tracking things in from outside.
One contributor to microplastic pollution is car tires, so that's going to be outside, and you can track them around on your feet. Degrading plastic from garbage and vehicle runoff can also get on your shoes.
Microplastics are in the air, they're in food, and they're in water. You can breathe them, eat them, and chemicals on them can also absorb into your skin.
I co-authored a systematic review of studies on microplastics last year. We found they may increase the risk of reproductive health effects, particularly for effects on sperm, as well as chronic inflammation and the potential to increase the risk of lung and colon cancer.
Then there are the chemicals used in plastic — like phthalates, which can disrupt testosterone levels and affect fetal development.
I would say leaving shoes at the door gradually happened over time. It wasn't too hard. It just became a habit.
We have a closet, a bench, and a cabinet for shoes.
One of my sons is very diligent about taking off his shoes when he goes in the house now. He lived in Japan for a couple months. He's got his house slippers.
My other kids also take their shoes off when they come in the house. It's a part of their cultural heritage. My husband's parents came from Japan, and they took their shoes off when they were in the house. We took the kids to Japan to visit relatives when they were small and almost everyone does it there. They identify with their Japanese heritage.
My daughter does it too in her townhouse with her roommates. They have one of those giant shelves with shoes on it.
At my home we have dogs, which I admit is a complicating factor because they're tracking stuff in all the time. I don't have a good solution to that at this point in time.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
15 minutes ago
- Forbes
Sell HIMS Stock Ahead of Its Earnings?
Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.
Yahoo
36 minutes ago
- Yahoo
SpaceX fires up Starship spacecraft ahead of 10th test flight (video, photos)
When you buy through links on our articles, Future and its syndication partners may earn a commission. SpaceX just fired up its newest Starship spacecraft on Thursday (July 31), to help prep the vehicle for an upcoming test flight. The company conducted a "static fire" trial with the 171-foot-tall (52 meters) Starship upper stage at its Starbase site in South Texas on Thursday, briefly igniting one of the vehicle's six Raptor engines. "Starship single-engine static fire demonstrating an in-space burn complete on Pad 1 at Starbase," SpaceX wrote in a Thursday evening X post that shared two photos and a video of the milestone. The test is part of the prep work for Flight 10 of Starship, the huge, fully reusable rocket that SpaceX is developing to help humanity colonize Mars and do a wide variety of other spaceflight work. Starship consists of two elements — the upper-stage spacecraft, called Starship or simply Ship, and a huge booster known as Super Heavy. Both are made of stainless steel and are powered by Raptors (33 of them in Super Heavy's case). This particular Ship is the second that SpaceX has earmarked for Flight 10. The first exploded on a test stand at Starbase on June 18 just before a planned static-fire test. The Super Heavy that will fly on Flight 10 has already passed its static-fire test, igniting all 33 of its engines on June 6. Related Stories: — SpaceX's Starship explodes in Texas during preparations for 10th test flight — SpaceX reached space with Starship Flight 9 launch, then lost control of its giant spaceship (video) — Starship and Super Heavy explained SpaceX has not yet announced a target date for Flight 10, but we may not have to wait long for it: company founder and CEO Elon Musk has said the test mission will launch in August. A fully stacked Starship first flew in April 2023. The huge rocket has launched three times so far this year, in January, March and May. On all three flights, SpaceX lost the upper stage before its planned Indian Ocean splashdown.
Yahoo
44 minutes ago
- Yahoo
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data